The Company, headquartered in Cranford, New Jersey, is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies. The Company’s strategy centers on achieving a market leading position by advancing innovative therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection.
Partnerships Integris Pharma S.A.: exclusive distribution agreement (October 7, 2025) to make LYMPHIR available via Named Patient Programs in Greece, Cyprus, Malta, Bulgaria, Romania, Croatia, Serbia, Albania, Bosnia Herzegovina, Kosovo, Montenegro and North Macedonia
Indications
Relapsed or refractory cutaneous T-cell lymphoma (CTCL)(Approved)
Status note Recombinant DNA-derived fusion protein (IL-2-diphtheria toxin). FDA approved August 8, 2024 for relapsed/refractory CTCL (improved formulation of prior ONTAK, commercial sales of ONTAK discontinued in 2014); launched December 2025. Two investigator-initiated Phase 1 immuno-oncology trials completed: LYMPHIR prior to commercial CD19-directed CAR-T (topline reported March 4, 2026) and LYMPHIR + PD-1 inhibitor in recurrent/metastatic solid tumors (NCT05200559, University of Pittsburgh; topline reported March 10, 2026).
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.